Published in Annu Rev Pharmacol Toxicol on January 01, 1998
Low-Fat Fish Oil Diet for Prostate Cancer Prevention | NCT00798876
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A (1999) 5.96
15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A (2000) 3.89
Prostaglandins and cancer. Gut (2005) 3.44
The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene (2009) 2.72
Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol (2005) 2.56
Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A (2000) 2.28
Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer (2001) 2.26
Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A (2001) 2.16
Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest (2004) 2.12
Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol (1999) 2.00
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol (2007) 1.95
Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res (2002) 1.90
The metabolic serine hydrolases and their functions in mammalian physiology and disease. Chem Rev (2011) 1.89
Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol (2010) 1.87
Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol (2004) 1.76
Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A (2000) 1.75
Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci U S A (2008) 1.69
Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol (2001) 1.66
Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol (1999) 1.65
Severe malarial anemia: innate immunity and pathogenesis. Int J Biol Sci (2011) 1.65
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci U S A (2002) 1.61
Periganglionic inflammation elicits a distally radiating pain hypersensitivity by promoting COX-2 induction in the dorsal root ganglion. Pain (2009) 1.61
The role of prostanoids in urinary bladder physiology. Nat Rev Urol (2012) 1.56
Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol (2011) 1.51
A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev Res (Phila) (2009) 1.51
Metabolic shifts in immunity and inflammation. J Immunol (2010) 1.45
Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J Mol Cell Cardiol (2003) 1.45
Fast synaptic inhibition in spinal sensory processing and pain control. Physiol Rev (2012) 1.45
Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation (2004) 1.43
Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships. Iran J Pharm Res (2011) 1.42
Optimization of multiplexed bead-based cytokine immunoassays for rat serum and brain tissue. J Neurosci Methods (2004) 1.41
Long-chain carboxychromanols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases. Proc Natl Acad Sci U S A (2008) 1.40
Uteroglobin represses allergen-induced inflammatory response by blocking PGD2 receptor-mediated functions. J Exp Med (2004) 1.36
Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br J Pharmacol (2006) 1.36
Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A (2012) 1.35
Nociception in cyclooxygenase isozyme-deficient mice. Proc Natl Acad Sci U S A (2000) 1.32
Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome. Mol Cancer Res (2010) 1.32
Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice. Basic Res Cardiol (2000) 1.31
Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther (2009) 1.31
Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest (2005) 1.30
The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond) (2010) 1.29
Cyclooxygenase-2 in synaptic signaling. Curr Pharm Des (2008) 1.26
Distinct monocyte gene-expression profiles in autoimmune diabetes. Diabetes (2008) 1.25
Vascular bed heterogeneity in age-related endothelial dysfunction with respect to NO and eicosanoids. Br J Pharmacol (2000) 1.25
PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. J Physiol (2006) 1.25
A receptor-grounded approach to teaching nonsteroidal antiinflammatory drug chemistry and structure-activity relationships. Am J Pharm Educ (2009) 1.24
Cyclooxygenase-2 expression is critical for chronic UV-induced murine skin carcinogenesis. Mol Carcinog (2007) 1.24
The nociceptive and anti-nociceptive effects of bee venom injection and therapy: a double-edged sword. Prog Neurobiol (2010) 1.23
Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci U S A (2001) 1.21
Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res (2002) 1.20
Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila) (2011) 1.20
Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull (2013) 1.18
Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia (2001) 1.18
Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression. J Virol (2006) 1.18
Cyclooxygenase in normal human tissues--is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J Cell Mol Med (2008) 1.18
Synthesis and Evaluation of Benzophenone-N-ethyl Morpholine Ethers as Anti-inflammatory Agents. Int J Biomed Sci (2010) 1.17
Effect of salicylate on the elasticity, bending stiffness, and strength of SOPC membranes. Biophys J (2005) 1.16
TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology (2013) 1.16
Regular aspirin use and lung cancer risk. BMC Cancer (2002) 1.15
Anti-inflammatory activity of the methanol extract of moutan cortex in LPS-activated Raw264.7 cells. Evid Based Complement Alternat Med (2007) 1.14
A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem J (2001) 1.14
Distinct roles of heterogeneous nuclear ribonuclear protein K and microRNA-16 in cyclooxygenase-2 RNA stability induced by S100b, a ligand of the receptor for advanced glycation end products. J Biol Chem (2008) 1.14
A heterogeneous mixture of F-series prostaglandins promotes sperm guidance in the Caenorhabditis elegans reproductive tract. PLoS Genet (2013) 1.14
Induction of COX-2 and PGE(2) biosynthesis by IL-1beta is mediated by PKC and mitogen-activated protein kinases in murine astrocytes. Br J Pharmacol (2000) 1.13
S-nitrosylation/activation of COX-2 mediates NMDA neurotoxicity. Proc Natl Acad Sci U S A (2008) 1.13
Post-training cyclooxygenase-2 (COX-2) inhibition impairs memory consolidation. Learn Mem (2002) 1.13
Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res (Phila) (2011) 1.13
Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol (2000) 1.12
Multiple signaling pathways are responsible for prostaglandin E2-induced murine keratinocyte proliferation. Mol Cancer Res (2008) 1.10
Cyclo-oxygenase-1 and -2 contribution to endothelial dysfunction in ageing. Br J Pharmacol (2000) 1.09
Vasoconstrictor prostanoids. Pflugers Arch (2010) 1.09
Mammalian class Sigma glutathione S-transferases: catalytic properties and tissue-specific expression of human and rat GSH-dependent prostaglandin D2 synthases. Biochem J (2001) 1.08
Endothelium-dependent contractions in SHR: a tale of prostanoid TP and IP receptors. Br J Pharmacol (2009) 1.07
Stress responses: the contribution of prostaglandin E(2) and its receptors. Nat Rev Endocrinol (2010) 1.07
The antioxidant mechanisms underlying the aged garlic extract- and S-allylcysteine-induced protection. Oxid Med Cell Longev (2012) 1.07
Activation of lipid metabolism contributes to interleukin-8 production during Chlamydia trachomatis infection of cervical epithelial cells. Infect Immun (2005) 1.07
Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin Pharmacol (2002) 1.06
NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells. Mol Cancer Ther (2009) 1.05
A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin. Br J Pharmacol (2000) 1.05
Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol (2009) 1.05
Molecular mechanisms contributing to necrotizing enterocolitis. Ann Surg (2001) 1.05
Host response to infection: the role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages. Infect Immun (2001) 1.04
Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo. Int J Mol Sci (2011) 1.04
COX-2 and cancer: a new approach to an old problem. Br J Pharmacol (2001) 1.02
Cyclooxygenases and prostaglandin E2 receptors in growth plate chondrocytes in vitro and in situ--prostaglandin E2 dependent proliferation of growth plate chondrocytes. Arthritis Res Ther (2006) 1.02
Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg (2002) 1.01
A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new diphenylamine derivatives. PLoS One (2007) 1.01
No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS One (2008) 1.01
Inhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimum. Int J Cancer (2007) 1.00
Identification and characterization of a cyclooxygenase-like enzyme from Entamoeba histolytica. Proc Natl Acad Sci U S A (2003) 0.99
COX-mediated endothelium-dependent contractions: from the past to recent discoveries. Acta Pharmacol Sin (2010) 0.99
Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol (2011) 0.99
Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut (2001) 0.99
Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol (1999) 0.99
Reduced cardiac remodeling and function in cardiac-specific EP4 receptor knockout mice with myocardial infarction. Hypertension (2008) 0.98
Cyclo-oxygenase-2 mediated prostaglandin release regulates blood flow in connective tissue during mechanical loading in humans. J Physiol (2003) 0.98
Application of the accurate mass and time tag approach in studies of the human blood lipidome. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.98
Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br J Pharmacol (2002) 0.98
Regulatory functions of the vascular endothelium. N Engl J Med (1990) 4.72
Report on the questionnaire on the organization of pharmacology in Great Britian. Br J Pharmacol Chemother (1966) 3.77
The mechanism of action of aspirin. Thromb Res (2003) 2.72
Pharmacokinetic function of the pulmonary circulation. Physiol Rev (1974) 2.52
New insights into the mode of action of anti-inflammatory drugs. Inflamm Res (1995) 2.29
Metabolism of the angiotensins in isolated perfused tissues. Nature (1969) 1.91
Removal of 5-hydroxytryptamine in the pulmonary circulation of rat isolated lungs. Br J Pharmacol (1970) 1.79
Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol (1995) 1.63
The release of biologically active substances from isolated lungs by 5-hydroxytryptamine and tryptamine. Br J Pharmacol (1970) 1.63
Second report on the organization of pharmacology in Great Britain. Br J Pharmacol (1974) 1.57
Pharmacodynamic profile of prostacyclin. Am J Cardiol (1995) 1.51
Anti-inflammatory drugs and their mechanism of action. Inflamm Res (1998) 1.48
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol (2006) 1.44
Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med (1998) 1.41
Mediators produced by the endothelial cell. Hypertension (1988) 1.38
Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. Proc Natl Acad Sci U S A (1999) 1.34
Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia. J Immunol (2000) 1.33
Nociception in cyclooxygenase isozyme-deficient mice. Proc Natl Acad Sci U S A (2000) 1.32
Uptake and inactivation of prostaglandin E2 methyl analogues in the rat pulmonary circulation. Br J Pharmacol (1978) 1.30
Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. Nature (1968) 1.27
Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme. Nature (1970) 1.27
Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol Suppl (1996) 1.25
Mechanism of action of antiinflammatory drugs. Int J Tissue React (1998) 1.18
Mechanism of action of aspirin-like drugs. Semin Arthritis Rheum (1997) 1.16
Differential release of eicosanoids by bradykinin, arachidonic acid and calcium ionophore A23187 in guinea-pig isolated perfused lung. Br J Pharmacol (1985) 1.14
The removal of noradrenaline in the pulmonary circulation of rat isolated lungs. Br J Pharmacol (1973) 1.12
Effects of cigarete smoke on metabolism of vasoactive hormones in rat isolated lungs [proceedings]. Br J Pharmacol (1978) 1.10
The inactivation of bradykinin in the pulmonary circulation of isolated lungs. Br J Pharmacol (1972) 1.07
The metabolism of 5-hydroxytryptamine and beta-phenylethylamine in perfused rat lung and in vitro. Br J Pharmacol (1979) 1.07
History of aspirin and its mechanism of action. Stroke (1990) 1.04
A better understanding of anti-inflammatory drugs based on isoforms of cyclooxygenase (COX-1 and COX-2). Adv Prostaglandin Thromboxane Leukot Res (1995) 1.02
Cellular and antiviral effects of halogenated deoxyribonucleosides. Ann N Y Acad Sci (1965) 1.00
Removal of 5-hydroxytryptamine by rat isolated lung. Br J Pharmacol (1970) 1.00
Altered prostaglandin synthesis in isolated lungs of rats with streptozotocin-induced diabetes. Thromb Res (1982) 0.99
Effects of sulphasalazine on prostaglandin inactivation and synthesis in isolated lungs of guinea pig, rat and man. Eur J Pharmacol (1980) 0.99
Differences in biological activation of arachidonic acid in perfused lungs from guinea pig, rat and man. Eur J Pharmacol (1980) 0.98
Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br J Pharmacol (2002) 0.98
Third Report on the Organization of Pharmacology in Great Britain. Br J Pharmacol (1986) 0.97
Metabolism of phenylethylamine in rat isolated perfused lung: evidence for monoamine oxidase 'type B' in lung. Br J Pharmacol (1976) 0.94
Cytokine-mediated induction of cyclo-oxygenase-2 by activation of tyrosine kinase in bovine endothelial cells stimulated by bacterial lipopolysaccharide. Br J Pharmacol (1995) 0.94
Metabolism and uptake of adenosine in rat isolated lung and its inhibition. Br J Pharmacol (1983) 0.93
Comparison of the induction of cyclooxygenase and nitric oxide synthase by endotoxin in endothelial cells and macrophages. Eur J Pharmacol (1995) 0.93
Effects of cigarette smoke on the metabolism of vasoactive hormones in rat isolated lungs. Br J Pharmacol (1979) 0.92
Reciprocal inhibition of nitric oxide and prostacyclin synthesis in human saphenous vein. Br J Pharmacol (1996) 0.90
Secretory functions of the vascular endothelium. J Physiol Pharmacol (1992) 0.89
Uptake of beta-phenylethylamine in rat isolated lung. Biochem Pharmacol (1980) 0.89
Action of prostaglandin dehydrogenase inhibitors on prostaglandin uptake in rat isolated lung. Br J Pharmacol (1979) 0.88
The mode of action of anti-inflammatory drugs. Postgrad Med J (1990) 0.88
Release of smooth muscle-contracting substances from isolated perfused lungs. Eur J Pharmacol (1976) 0.87
Tumor growth, angiogenesis and inflammation in mice lacking receptors for platelet activating factor (PAF). Life Sci (2007) 0.87
Different mechanisms underlie the analgesic actions of paracetamol and dipyrone in a rat model of inflammatory pain. Br J Pharmacol (2007) 0.87
Release of spasmogenic substances induced by vasoactive amines from isolated lungs. Br J Pharmacol (1972) 0.87
Sequential changes in lung metabolism, permeability, and edema after ANTU. J Appl Physiol (1985) (1987) 0.87
Decreased inactivation of prostaglandin E2 in isolated lungs from rats with alpha-naphthyl thiourea-induced pulmonary oedema. Biochem Pharmacol (1982) 0.86
Inactivation of monoamines by the lung. Ciba Found Symp (1980) 0.86
Tryptamine receptors in rat pulmonary artery. Br J Pharmacol (1974) 0.86
Inflammatory responses induced by poly-L-arginine in rat lungs in vivo. Agents Actions (1993) 0.86
Murine chemokine CXCL2/KC is a surrogate marker for angiogenic activity in the inflammatory granulation tissue. Microcirculation (2005) 0.86
Human RANTES acts as a receptor antagonist for guinea pig eotaxin in vitro and in vivo. J Immunol (1996) 0.85
The bradykininase activities of extracts of dog lung. Br J Pharmacol (1973) 0.85
Effect of the oestrous cycle and exogenous steroids on metabolism of 5-hydroxytryptamine by monoamine oxidase from rat lung [proceedings]. J Physiol (1978) 0.85
Metabolism of vasoactive hormones in human isolated lung. Clin Sci (Lond) (1980) 0.85
Uptake of E-type prostaglandins by rat isolated lung [proceedings]. J Physiol (1977) 0.85
Endothelins. Blood Vessels (1990) 0.85
Cyclooxygenase-2 and its regulation in inflammation. Mediators Inflamm (1996) 0.84
Pulmonary metabolism of bradykinin analogues and the contribution of angiotensin converting enzyme to bradykinin inactivation in isolated lungs. Br J Pharmacol (1977) 0.84
Phospholipases A2 and C of human lung; subcellular distribution and substrate selectivity. Biochim Biophys Acta (1989) 0.84
Endogenous opioids mediate the hypoalgesia induced by selective inhibitors of cyclo-oxygenase 2 in rat paws treated with carrageenan. Neuropharmacology (2006) 0.83
Clinically-used dyes are inhibitors of prostaglandin E2 inactivation in rat isolated lung [proceedings]. Br J Pharmacol (1978) 0.83
Regulatory mechanisms of the vascular endothelium: an update. Pol J Pharmacol (1995) 0.82
Characteristics of the angiotensin I converting enzyme from dog lung. Nat New Biol (1971) 0.82
Host response to sponge implants differs between subcutaneous and intraperitoneal sites in mice. J Biomed Mater Res B Appl Biomater (2007) 0.82
Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats. Neuropharmacology (2010) 0.82
Selective effect of pulmonary oedema on prostaglandin E2 pharmacokinetics in rat lung. Biochem Pharmacol (1985) 0.82
Inhibition of angiotensin I converting enzyme by venom peptides. Br J Pharmacol (1971) 0.82
Fate of arachidonic acid in guinea-pig isolated lungs [proceedings]. J Physiol (1978) 0.82
Effect of pulmonary oedema induced by alpha-naphthylthiourea on synthesis of cyclo-oxygenase products in rat isolated lungs. Prostaglandins (1985) 0.81
Sites of uptake of 3H-5-hydroxytryptamine in rat isolated lung. Histochemistry (1974) 0.81
Metabolism of 14C-arachidonate in rat isolated lung. Prostaglandins (1980) 0.81
Pulmonary angiotensin-converting enzyme and its inhibition: a historical survey. Ciba Found Symp (1980) 0.81
Mediators from the endothelial cell and their participation in inflammation. Int J Tissue React (1994) 0.81
The inactivation of endogenous amines in lung. Agents Actions (1976) 0.80
Effects of high oxygen tension on the metabolism of vasoactive hormones in isolated perfused rat lungs. Acta Physiol Scand (1981) 0.80
The fate of exogenous arachidonic acid in guinea-pig isolated lung. J Physiol (1979) 0.80
Peripheral mu-, kappa- and delta-opioid receptors mediate the hypoalgesic effect of celecoxib in a rat model of thermal hyperalgesia. Life Sci (2010) 0.80
Dual effects of Rho-kinase inhibitors on a rat model of inflammatory pain. Pain Res Manag (2014) 0.79
Metabolism of beta-phenylethylamine in rat lung during the oestrous cycle [proceedings]. J Physiol (1978) 0.79
The future of NSAID therapy: selective COX-2 inhibitors. Int J Clin Pract (2000) 0.79
Effects of halothane on pulmonary inactivation of noradrenaline and prostaglandin E2 in anaesthetized dogs. Clin Sci Mol Med (1976) 0.79
The fate of adenine nucleotides in the pulmonary circulation of isolated lung. Q J Exp Physiol (1983) 0.79
Effects of Ph CL 28A on eicosanoid synthesis in rat isolated hearts. Prostaglandins (1991) 0.78
Cationic factors affecting phospholipase activities from human lung. Br J Pharmacol (1990) 0.78
Biosynthesis of prostaglandins and thromboxanes in lung. Bull Eur Physiopathol Respir (1981) 0.78
Endogenous opioid and cannabinoid mechanisms are involved in the analgesic effects of celecoxib in the central nervous system. Pharmacology (2012) 0.78
Exposure to oxygen inhibits metabolism of vasoactive hormones in rat isolated lung [proceedings]. J Physiol (1979) 0.78
Mechanism of action of anti-inflammatory drugs. Adv Exp Med Biol (1997) 0.77
Synthesis and catabolism of cyclo-oxygenase products. Br Med Bull (1983) 0.77
Metabolism of angiotensin and bradykinin in rat isolated lungs during the oestrous cycle [proceedings]. J Physiol (1979) 0.77
Effects of platelet activating factor (PAF) and other vasoconstrictors on a model of angiogenesis in the mouse. Int J Exp Pathol (1992) 0.77
Inhibition by clinically used dyes of prostaglandin inactivation in rat and human lung. Br J Pharmacol (1981) 0.77